Results 51 to 60 of about 6,404 (193)

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6584-6594, August 2026.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas   +11 more
wiley   +1 more source

Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines

open access: yesnpj Vaccines, 2022
Zoster vaccines generate antibody responses against varicella-zoster virus (VZV). We compared antibody-dependent cell cytotoxicity (ADCC) elicited by zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV).
Seong Yeon Park   +5 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

open access: yesEuropean Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni   +4 more
wiley   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

open access: yesJournal of Gastroenterology and Hepatology, Volume 41, Issue 7, Page 2006-2029, July 2026.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi   +34 more
wiley   +1 more source

Recombinant zoster (shingles) vaccine, RZV : what you need to know [PDF]

open access: yes
Shingles (also called herpes zoster, or just zoster) is a painful skin rash, often with blisters. Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox.

core   +1 more source

Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024

open access: yesFrontiers in Medicine
BackgroundHerpes Zoster (HZ) is a viral skin disease caused by reactivation of latent Varicella Zoster Virus (VZV) in human ganglia, presenting with unilateral neuropathic pain and vesicular rash.
Wenli Gao   +5 more
doaj   +1 more source

Herpes zoster infection in patients with inflammatory bowel disease [PDF]

open access: yesThe Korean Journal of Internal Medicine
Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ), particularly those receiving immunosuppressive treatments such as corticosteroids, thiopurines, and biologics, which elevate the likelihood of varicella-zoster ...
Dong Hyun Kim, Sang-Bum Kang
doaj   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Barbara Eichhorst   +13 more
wiley   +1 more source

A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates

open access: yesFrontiers in Immunology
Herpes zoster (HZ), also known as shingles, remains a significant global health issue and most commonly seen in elderly individuals with an early exposure history to varicella-zoster virus (VZV).
Yuanyuan Li   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy